Results 251 to 260 of about 174,708,283 (296)

Mammalian target of rapamycin as a therapeutic target in osteoporosis

Journal of Cellular Physiology, 2017
The mechanistic target of rapamycin (mTOR) plays a key role in sensing and integrating large amounts of environmental cues to regulate organismal growth, homeostasis, and many major cellular processes. Recently, mounting evidences highlight its roles in regulating bone homeostasis, which sheds light on the ...
Gengyang Shen, Hui Ren, Ting Qiu, Zhida Zhang, Wenhua Zhao, Xiang Yu, Jinjing Huang, Jingjing Tang, De Liang, Zhensong Yao, Zhidong Yang, Xiaobing Jiang   +11 more
openaire   +2 more sources

Role of Mammalian Target of Rapamycin in Atherosclerosis

Current Molecular Medicine, 2018
The mammalian target of rapamycin (mTOR) regulates multiple pathophysiological processes, such as cell development, angiogenesis, autophagy, as well as innate-adaptive immune responses. Numerous studies have demonstrated that mTOR signaling plays an important role in the process of atherosclerosis (AS) itself ...
Z, Cai, Y, He, Y, Chen
openaire   +2 more sources

Mammalian target of rapamycin signaling in the podocyte

Current Opinion in Nephrology and Hypertension, 2012
Mammalian target of rapamycin (mTOR) is an evolutionarily conserved protein kinase. mTOR forms two distinct functional multiprotein kinase complexes that mutually phosphorylate different substrates and regulate a wide array of essential cellular processes including translation, transcription and autophagy.
Inoki, Ken, Huber, Tobias B.
openaire   +3 more sources

Mammalian Target of Rapamycin Inhibitor-Associated Stomatitis

Future Oncology, 2013
With the recent introduction of inhibitors of mammalian target of rapamycin (mTOR) in oncology, distinct cutaneous and oral adverse events have been identified. In fact, stomatitis and rash are documented as the most frequent and potentially dose-limiting side effects.
Boers-Doets, C.B., Raber-Durlacher, J.E., Treister, N.S., Epstein, J.B., Arends, A.B.P., Wiersma, D.R., Lalla, R.V., Logan, R.M., van Erp, N.R.P., Gelderblom, H.   +9 more
openaire   +6 more sources

Inhibitors of mammalian target of rapamycin

Drugs of the Future, 2001
The first generation of immunosuppressants such as azathioprine, steroids and anti-lymphocyte-globulins did not provide long-term graft survival in many transplant recipients. After the introduction of calcineurin inhibitors, solid organ transplantation became a standard therapy for many end-stage organ failures and immunosuppressive therapy was later ...
null Klupp, J., null Langrehr, J.M., null Junge, G., null Neuhaus, P.   +3 more
openaire   +1 more source

The rationale of targeting mammalian target of rapamycin for ischemic stroke

Cellular Signalling, 2013
Given the current limitation of therapeutic approach for ischemic stroke, a leading cause of disability and mortality in the developed countries, to develop new therapeutic strategies for this devastating disease is urgently necessary. As a serine/threonine kinase, mammalian target of rapamycin (mTOR) activation can mediate broad biological activities ...
Zhao Zhong, Chong, Qingqiang, Yao, Hui-Hua, Li   +2 more
openaire   +2 more sources

Mammalian target of rapamycin inhibitors in sarcomas

Current Opinion in Oncology, 2006
Sarcomas are a rare malignancy accounting for less than 1% of all cancers diagnosed annually. Standard chemotherapy has a response rate of around 25% and newer agents are needed to improve the outcome in patients with advanced sarcomas. The mammalian target of rapamycin plays a central role in cell growth, proliferation, and apoptosis and its ...
openaire   +2 more sources

The Role of Targeting Mammalian Target of Rapamycin in Lung Cancer

Clinical Lung Cancer, 2008
The expression of mammalian target of rapamycin (mTOR) might be upregulated by various mechanisms in lung cancer pathogenesis, and its activity might be modulated by pathways related to tobacco-mediated carcinogenesis. Furthermore, preclinical data suggest an antitumor effect in lung cancer from a class of agents that antagonize the mTOR pathway ...
Sumanta Kumar, Pal, Robert A, Figlin, Karen L, Reckamp   +2 more
openaire   +2 more sources

Targeting mammalian target of rapamycin (mTOR) for health and diseases

Drug Discovery Today, 2007
The macrolide rapamycin is used clinically to treat graft rejection and restenosis. Mammalian target of rapamycin (mTOR) is a central controller of cellular and organism growth that integrates nutrient and hormonal signals, and regulates diverse cellular processes.
Chi Kwan, Tsang, Haiyan, Qi, Leroy F, Liu, X F Steven, Zheng   +3 more
openaire   +2 more sources

Mammalian target of rapamycin (mTOR) inhibitors

Current Oncology Reports, 2004
Current efforts in anticancer drug development are targeting key factors in cell-cycle regulation. Mammalian target of rapamycin (mTOR) is one such protein kinase that facilitates cell growth by stimulating the cell to traverse the G1 to S phase of the cell cycle.
openaire   +2 more sources